In CRC, altered dystrophin (DMD, a musculo-cellar protein) expression was linked to the onset and progression of cancer, including myogenic tumors and even non-myogenic tumors, and it is considered as a new regulatory factor in tumor development and a new prognostic factor for tumor progression and the survival of CRC patients. The gene discussed is DMD; the disease is neoplasm.